Skip to content

Study · Animal study (in vivo) · 2018

3 results

Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis.

Carion TW, Ebrahim AS, Kracht D, Agrawal A, Strand E, Kaddurah O, McWhirter CR, Sosne G, Berger EA

Cells20 Sept 2018Cited by 18 (Europe PMC)

PMID30241380 (opens in a new tab)PMCIDPMC6210523 (opens in a new tab)DOI10.3390/cells7100145 (opens in a new tab)PepBankPUB-30241380
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

With increasing multidrug resistance and contraindication for corticosteroid use, the goal of this study was to develop thymosin beta-4 (Tβ4) as an adjunctive therapy to antibiotics for the treatment of bacterial keratitis that effectively promotes enhanced wound healing, host defense, and inflammation resolution. Disease outcome was assessed by clinical score, slit lamp photography, and histopathology. Cytokine profile, bacterial load, PMN infiltration, and Griess and reactive oxygen species (ROS) levels were determined. Adjunct Tβ4 treatment resulted in a significant improvement compared to PBS, Tβ4, and most remarkably, ciprofloxacin, correlating with changes in mediators of inflammation and wound healing. Collectively, these data provide evidence that wound healing is an essential aspect in the development of new therapies to treat corneal infection. Use of adjunctive Tβ4 provides a more efficacious approach for bacterial keratitis by addressing both the infectious pathogen and deleterious host response.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Pseudomonas aeruginosa keratitis, adding thymosin beta‑4 to ciprofloxacin improved disease outcome significantly versus ciprofloxacin alone.

    In plain wordsIn bacterial eye infection, adding thymosin beta‑4 to ciprofloxacin gave better outcomes than ciprofloxacin alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedKeratitis disease outcome
    Study

    n: not reported in source

    Comparator
    Ciprofloxacin alone
    Outcome group
    Infection and antimicrobial activity · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adjunct Tβ4 treatment resulted in a significant improvement compared to PBS, Tβ4, and most remarkably, ciprofloxacin, correlating with changes in mediators of inflammation and wound healing.
    1 context sentence
    Summary · context
    Disease outcome was assessed by clinical score, slit lamp photography, and histopathology.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In Pseudomonas aeruginosa keratitis, adjunct treatment with thymosin beta‑4 and ciprofloxacin improved disease outcome significantly versus PBS.

    In plain wordsIn bacterial eye infection, thymosin beta‑4 plus ciprofloxacin gave better outcomes than PBS.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedKeratitis disease outcome
    Study

    n: not reported in source

    Comparator
    PBS
    Outcome group
    Infection and antimicrobial activity · Eye

    Source sentences

    Summary
    Adjunct Tβ4 treatment resulted in a significant improvement compared to PBS
    1 context sentence
    Summary · context
    Disease outcome was assessed by clinical score, slit lamp photography, and histopathology.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In Pseudomonas aeruginosa keratitis, adjunct treatment with thymosin beta‑4 and ciprofloxacin improved disease outcome significantly versus thymosin beta‑4 alone.

    In plain wordsIn bacterial eye infection, thymosin beta‑4 plus ciprofloxacin gave better outcomes than thymosin beta‑4 alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedKeratitis disease outcome
    Study

    n: not reported in source

    Comparator
    Thymosin beta-4 alone
    Outcome group
    Infection and antimicrobial activity · Eye

    Source sentences

    Summary
    Adjunct Tβ4 treatment resulted in a significant improvement compared to PBS, Tβ4, and most remarkably, ciprofloxacin, correlating with changes in mediators of inflammation and wound healing.
    1 context sentence
    Summary · context
    Disease outcome was assessed by clinical score, slit lamp photography, and histopathology.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.